/
BIAFW
$0.14-$0.00 (-0.50%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.05 – $0.81
11% from low
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NASDAQ
WARRANT
Price (6 mo)
Loading chart…
Change$-1.96
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $4.8K | $2.5M | $9.4M | $6.2M |
| Cost of revenue | $40.3K | $22.2K | $4.8K | $467 | $1.7M | $6.0M | $4.7M |
| Gross profit | −$40.3K | −$22.2K | −$4.8K | $4.3K | $791.6K | $3.4M | $1.4M |
| Gross margin | — | — | — | 90.3% | 31.3% | 36.1% | 23.2% |
| R&D | $1.9M | $1.6M | $1.1M | $1.5M | $1.7M | $1.8M | $2.1M |
| Operating income | −$3.1M | −$2.6M | −$2.2M | −$4.0M | −$8.0M | −$9.0M | −$10.6M |
| EBITDA | −$3.0M | −$6.9M | −$5.3M | −$5.6M | −$7.6M | −$8.3M | −$14.3M |
| Net income | −$3.3M | −$7.3M | −$6.3M | −$8.2M | −$7.9M | −$9.0M | −$14.9M |
| Net margin | — | — | — | -169771.2% | -313.5% | -96.6% | -242.0% |
| EPS (diluted) | -13.50 | -29.70 | -69.57 | -54.30 | -27.30 | -22.50 | -8.66 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $7M | $-8.10 | $-8.10–$-8.10 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
bioAffinity Technologies, Inc. Warrant
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
www.bioaffinitytech.com- Employees
- 57
- IPO / List date
- Aug 10, 2022
- HQ
- SAN ANTONIO, TX
Held by traders on TradeandTell
No one on the platform currently holds BIAFW.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in BIAFW as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded BIAFW yet.